Skip to main content

Intralesional Corticosteroids

Intralesional corticosteroids — primarily triamcinolone acetonide — are used across urology as anti-inflammatory and anti-fibrotic adjuncts rather than stand-alone therapies. The most guideline-supported indications are submucosal injection for Hunner lesions in IC/BPS (AUA Grade C) ; stricture/BNC injections have more uncertain, largely off-label evidence. Other applications include genital lichen sclerosus / lichen planus, BXO at preputioplasty, vesicourethral anastomotic stenosis (VUAS) after RP, and ureteroenteric anastomotic strictures.[1][2][3]

For related agents, see High-potency topical corticosteroids, Topical calcineurin inhibitors, Antimitotics / antifibrotics (mitomycin C), Platelet-rich plasma, and Intravesical IC/BPS agents.

Mechanism in urologic fibrotic and inflammatory disease​

Triamcinolone acetonide acts through:[4][5]

  • Anti-inflammatory — phospholipase-A2 inhibition → reduced prostaglandins / leukotrienes; decreased capillary permeability and leukocyte migration
  • Anti-fibrotic — suppression of fibroblast proliferation and collagen synthesis; reduced MMP-3 and TGF-β expression in treated bladder-neck tissue[6]
  • Local immunomodulation with minimal systemic exposure when properly dosed

Published urologic protocols often use triamcinolone acetonide suspension. Formulations and routes are not interchangeable: the cited US Kenalog-40/80 label is for intramuscular or intra-articular use, not intradermal injection; these urologic injections require a deliberately selected off-label protocol and pharmacy verification.[5]

IC/BPS — Hunner lesions (AUA-recommended)​

AUA IC/BPS guideline 2022 (Recommendation; Grade C): if Hunner lesions are present, fulguration with electrocautery and/or injection of triamcinolone should be performed.[3]

Technique​

Endoscopic submucosal injection of triamcinolone directly into and around Hunner lesions under cystoscopic guidance.[7]

Efficacy​

StudynFinding
Funaro 201836Pain VAS 8.3 → 3.8 (p < 0.001); 70% had sustained improvement at 12-mo follow-up[7]
Mateu 201720VAS 8 → 2.5 (p < 0.001) with lower-dose low-concentration technique[8]

Triamcinolone injection is one of the few IC/BPS therapies producing months-long improvement after a single procedure, though periodic retreatment is typically necessary.[3] See Intravesical IC/BPS agents for the broader instillation and injection framework.

Urethral stricture — adjunct to internal urethrotomy​

Intralesional corticosteroid is one of the most-studied adjuncts to internal urethrotomy (IU) / urethral dilation.

Meta-analytic evidence​

  • Pang 2021 systematic review and meta-analysis (26 studies) — any adjunct to minimally invasive stricture treatment lowered recurrence (OR 0.37; 95% CI 0.27–0.50; p < 0.001). Mitomycin C had the strongest signal (intralesional OR 0.23; 95% CI 0.11–0.48) — indirect pooled comparisons do not establish a preferred injectable[9]
  • Zhang 2014 meta-analysis (8 RCTs, n = 203) — local steroids + IU prolonged time to recurrence (mean 10.14 vs 5.07 months; p < 0.001)[10]
  • Jacobs 2021 systematic review — the positive clinical effect of steroids appears to decrease with longer follow-up, suggesting a time-limited anti-fibrotic benefit[11]

Technique​

Triamcinolone acetonide 40 mg/mL injected submucosally at the stricture site at 4–8 points via cystoscopic injection needle, either at the time of urethrotomy or as a postoperative series.[12][13] The original Sharpe-Finney 1976 series (n = 96) established the technique and noted particular utility for distal / meatal strictures and post-RP anastomotic strictures.[12]

Agent comparison: current EAU guidance limits intralesional post-DVIU injections to clinical trials; there is no established default MMC-versus-steroid sequence.[31] See Antimitotics / antifibrotics.[9]

Bladder-neck contracture and post-RP VUAS​

BNC after TURP / open prostatectomy and VUAS after radical prostatectomy both carry high recurrence rates after endoscopic treatment alone. Triamcinolone has been studied as an adjunct, but uncontrolled outcomes cannot establish its incremental benefit.

Post-TURP BNC​

  • Zhang 2021 — 28 patients with highly recurrent BNC (mean recurrence interval 2.2 months) treated with transurethral resection + intra- and postoperative triamcinolone injections (40 mg/mL at 8 points, repeated q4 wk × 3) — 92.9% success at median 2.8-year follow-up[13]

  • Sun 2022 — 180-W GreenLight laser vaporization with repeated triamcinolone injections (n = 46) — zero recurrence during follow-up; significant improvement in Qmax, IPSS, QoL, PVR. Immunohistochemistry showed reduced collagen I, MMP-3, and TGF-β in treated tissue[6]

  • Palminteri–Ferrari 2024 BNC series — an uncontrolled bladder-neck-contracture technique report, not a general VUAS protocol. Do not extrapolate quadrant incisions to post-RP/radiated stenosis; deep 6/12-o’clock cuts risk rectal injury or urosymphyseal fistula.[16][31]

Post-RP VUAS​

  • Eltahawy 2008 — Holmium laser incision at 3 and 9 o'clock with triamcinolone at incision sites — 19 patients with patency (reported as 83%; the abstract enrolled 24 and has a denominator inconsistency) at mean 24-mo follow-up[14]
  • Kravchick 2013 — TRUS-guided injection of long-acting steroids into the scar area after dilation had the highest efficiency quotient among treatment modalities, with lower retreatment rates and no incontinence vs cold-knife urethrotomy or TUR[15]

Peyronie's disease — not recommended​

Intralesional corticosteroids have a long history but limited supporting evidence and are not recommended by current guidelines as a preferred intralesional agent.

  • AUA PD guideline 2015 — intralesional corticosteroids (dexamethasone, betamethasone + hyaluronidase + lidocaine) have been studied but have not consistently shown efficacy in placebo-controlled trials[17][4]
  • Rosenberg 2023 Cochrane review — very low certainty evidence for intralesional betamethasone vs saline; uncertain effects on curvature (RR 0.75; 95% CI 0.20–2.79; single small study, n = 30)[18]
  • Manfredi 2025 SR on acute-phase PD injection therapy — corticosteroids showed variable efficacy with favorable safety, but overall evidence quality is low[19]
  • Ure 2021 non-randomized methylprednisolone 40 mg weekly × 8 weeks (n = 48 acute-phase) — significant reductions in plaque size (13.6 → 10.8 mm; p = 0.025) and PDQ scores; no AEs[20]

Why not preferred​

  • Risk of tunical atrophy and local tissue thinning with repeated injection
  • Potential worsening of erectile function
  • Other agents have differing guideline support: CCH has randomized evidence, whereas EAU finds insufficient support for intralesional verapamil. There is no uniform all-society endorsement of every injection.[18][21][22][33]

See Peyronie's disease agents for the broader PD intralesional comparison.

Genital lichen sclerosus and lichen planus​

Intralesional corticosteroids are a selected specialist option for adult vulvar LS that remains active despite appropriate topical therapy. The German S3 guideline gives an open recommendation, not evidence of proven comparative benefit. Biopsy a resistant hyperkeratotic plaque to exclude neoplasia before injection. Choose concentration, volume, depth and interval for the particular lesion and formulation; there is no universal safe 40-mg vulvar ceiling.[2][23][34]

Intraurethral clobetasol for penile / urethral LS​

  • Potts 2016 — intraurethral clobetasol applied with a catheter/dilator — 89% success in a selected observational series at mean 24.8-month follow-up. Most responders continued treatment; avoidance of escalation during follow-up is not a permanent cure or proof that medication reverses established fibrosis.[24][34]
  • Hayden 2020 — topical + intraurethral clobetasol improved AUASS 12 → 8 and QoL bother 4 → 2; 85.7% avoided surgery[25]

BXO in children — Wilkinson 2012​

An observational comparison reported 81% fully retractile foreskin after preputioplasty plus intralesional triamcinolone, and meatal stenosis rates of 6% versus 19% in the circumcision group at approximately 14 months. Treatment selection and the combined intervention limit causal interpretation; this does not establish superiority over circumcision.[26] See High-potency topical corticosteroids for the first-line topical framework in LS.

Ureteroenteric anastomotic strictures​

Triamcinolone has been incorporated into endoscopic management of benign UEAS after urinary diversion.

  • Katims 2021 — 24 UEAS treated with laser incision + triamcinolone + balloon dilation to 24F + temporary stenting — 83.3% success at median 30-month follow-up[27]
  • Meretyk 1992 — early endoureterotomy experience suggested triamcinolone into the stricture bed favorably influenced subsequent ureteral patency[28]

Idiopathic bulbar urethritis​

Ashraf 2017 pilot (n = 14 boys with idiopathic bulbar urethritis — hematuria ± dysuria without infection) — cystoscopy-guided instillation of 40 mg triamcinolone — 85.7% complete or partial resolution, though 50% required at least one additional treatment.[29]

Published dosing examples — not a universal protocol​

Concentration alone is not a dose. Total exposure, dilution, route, excipients and site-specific technique require verification; the studies below are heterogeneous and do not establish routine scheduling.

IndicationTypical doseTechniqueFrequency
Hunner lesions (IC/BPS)Variable low-dose submucosalEndoscopic submucosal injection into / around lesionsSingle session; retreat PRN (~10–12 mo)[3][7][8]
Urethral stricture40 mg/mL at 4–8 pointsSubmucosal injection at urethrotomy siteAt IU ± postoperative series[9][12]
Bladder-neck contracture80 mg (2 mL of 40 mg/mL) at 8 pointsCystoscopic injection at incision sitesIntraop + q4 wk × 3 postop[13][6]
VUAS post-RP40 mg at incision sitesTransurethral or TRUS-guidedAt incision; repeat PRN[14][15][16]
Vulvar LSIndividualized concentration and total volumeSelected refractory plaques after excluding neoplasiaSpecialist-directed; no universal vulvar dose ceiling[23][34]
BXO — pediatricIntralesional at preputioplastyInjection into BXO-affected tissueAt time of preputioplasty[26]
Ureteroenteric strictureInto stricture bedAntegrade / ureteroscopic injectionAt laser incision[27]

Safety​

Generally well tolerated when dosed appropriately; complications are mild and localized in most series.

ConcernDetails
UTI2.9–14% with urethral steroid injection[9]
Bleeding8.8%
Extravasation5.8%
Iatrogenic Cushing's syndromeTwo pediatric cases reported after intralesional triamcinolone for urethral strictures — an old case report does not establish a safe alternative formulation, dose or interval for children[30]
Tissue atrophyRecognized local corticosteroid risk; especially relevant with repeated injection and thin genital skin[5]
Systemic steroid effectsImpaired wound healing, hyperglycemia, adrenal suppression with repeated high doses, immunosuppression[5]

Evidence Summary​

IndicationEvidence levelKey source
IC/BPS Hunner lesionsGuideline (AUA Grade C)Clemens 2022[3]; Funaro 2018[7]; Mateu 2017[8]
Urethral stricture adjunctLevel 1 (multiple meta)Pang 2021[9]; Zhang 2014[10]; Jacobs 2021[11]
Bladder-neck contractureLevel 3 (retrospective)Zhang 2021 92.9%[13]; Sun 2022 zero recurrence with IHC correlate[6]
VUAS post-RPLevel 3Eltahawy 2008[14]; Kravchick 2013[15]; Palminteri 2024[16]
Peyronie's diseaseVery low (Cochrane)Rosenberg 2023[18]; AUA 2015[17]
Vulvar LS / LP (refractory)Limited evidence; selected specialist useACOG 224[2]; S3 guideline for LS[34]
Penile / urethral LSLevel 3Potts 2016[24]; Hayden 2020[25]
Pediatric BXO at preputioplastyLevel 3Wilkinson 2012[26]
Ureteroenteric stricturesLevel 3Katims 2021[27]

Clinical Positioning​

  • For Hunner lesions, triamcinolone injection may be used with or without fulguration. The AUA recommendation does not require the combination.[3]
  • Stricture adjuncts are not a routine MMC-first sequence. EAU limits intralesional post-DVIU agents to clinical trials. Posterior BNC/VUAS series do not prove which injection or schedule is best.[31]
  • Do not generalize study injection/incision recipes across anatomy. Current label formulation restrictions and posterior injury risks matter even where selected off-label use is supported.[5][31]
  • Intralesional corticosteroids are not established Peyronie therapy. See the dedicated agent page for the different levels of support for CCH, interferon and verapamil.[17][18][21][22]
  • For refractory genital LS, exclude neoplasia before injection and use specialist site-specific dosing rather than treating 40 mg as a universal safe vulvar ceiling.[2][23]
  • Pediatric BXO preputioplasty evidence is limited. EAU recommends circumcision for BXO or treatment-refractory phimosis; a small foreskin-preservation series does not establish superiority.[1][26][32]
  • Cushing syndrome, adrenal suppression and tissue atrophy remain possible. Small-study adverse-event percentages are not safety ceilings, and an old pediatric report is not a modern dosing standard.[5][30]

See Also​

References​

1. Moreno G, Ramirez C, Corbalán J, et al. "Topical corticosteroids for treating phimosis in boys." Cochrane Database Syst Rev. 2024;1:CD008973. doi:10.1002/14651858.CD008973.pub3

2. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin Summary, Number 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945

3. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

4. Trost LW, Gur S, Hellstrom WJ. "Pharmacological management of Peyronie's disease." Drugs. 2007;67(4):527–545. doi:10.2165/00003495-200767040-00004

5. DailyMed. Kenalog-40/80 (triamcinolone acetonide injectable suspension) prescribing information. Label. Accessed September 12, 2026.

6. Sun X, Jin X, Leng K, Zhao Y, Zhang H. "180-W GreenLight laser photoselective vaporization with multiple triamcinolone acetonide injections for the treatment of bladder neck contractures." Lasers Med Sci. 2022;37(8):3115–3121. doi:10.1007/s10103-022-03568-2

7. Funaro MG, King AN, Stern JNH, Moldwin RM, Bahlani S. "Endoscopic injection of low dose triamcinolone: a simple, minimally invasive, and effective therapy for interstitial cystitis with Hunner lesions." Urology. 2018;118:25–29. doi:10.1016/j.urology.2018.03.037

8. Mateu L, Izquierdo L, Franco A, et al. "Pain relief after triamcinolone infiltration in patients with bladder pain syndrome with Hunner's ulcers." Int Urogynecol J. 2017;28(7):1027–1031. doi:10.1007/s00192-016-3213-3

9. Pang KH, Chapple CR, Chatters R, et al. "A systematic review and meta-analysis of adjuncts to minimally invasive treatment of urethral stricture in men." Eur Urol. 2021;80(4):467–479. doi:10.1016/j.eururo.2021.06.022

10. Zhang K, Qi E, Zhang Y, Sa Y, Fu Q. "Efficacy and safety of local steroids for urethra strictures: a systematic review and meta-analysis." J Endourol. 2014;28(8):962–968. doi:10.1089/end.2014.0090

11. Jacobs ME, de Kemp VF, Albersen M, de Kort LMO, de Graaf P. "The use of local therapy in preventing urethral strictures: a systematic review." PLoS One. 2021;16(10):e0258256. doi:10.1371/journal.pone.0258256

12. Sharpe JR, Finney RP. "Urethral strictures: treatment with intralesional steroids." J Urol. 1976;116(4):440–443. doi:10.1016/s0022-5347(17)58850-3

13. Zhang L, Liu S, Wu K, Mu X, Yang L. "Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections." World J Urol. 2021;39(2):527–532. doi:10.1007/s00345-020-03224-w

14. Eltahawy E, Gur U, Virasoro R, Schlossberg SM, Jordan GH. "Management of recurrent anastomotic stenosis following radical prostatectomy using Holmium laser and steroid injection." BJU Int. 2008;102(7):796–798. doi:10.1111/j.1464-410X.2008.07919.x

15. Kravchick S, Lobik L, Peled R, Cytron S. "Transrectal ultrasonography-guided injection of long-acting steroids in the treatment of recurrent / resistant anastomotic stenosis after radical prostatectomy." J Endourol. 2013;27(7):875–879. doi:10.1089/end.2012.0661

16. Palminteri E, Morselli S, Cindolo L, et al. "Iatrogenic or recurrent bladder neck contracture treated by the Palminteri-Ferrari technique: a new way to approach a frustrating condition." World J Urol. 2024;42(1):195. doi:10.1007/s00345-024-04912-7

17. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's disease: AUA guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

18. Rosenberg JE, Ergun O, Hwang EC, et al. "Non-surgical therapies for Peyronie's disease." Cochrane Database Syst Rev. 2023;7:CD012206. doi:10.1002/14651858.CD012206.pub2

19. Manfredi C, Russo GI, Capogrosso P, et al. "Injection therapy in the acute phase of Peyronie's disease: a systematic review of current evidence." J Sex Med. 2025;22(5):799–812. doi:10.1093/jsxmed/qdaf044

20. Ure I, Ozen A. "Intralesional low-dose methylprednisolone for the treatment of active-phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study." Int J Clin Pract. 2021;75(3):e13754. doi:10.1111/ijcp.13754

21. Chierigo F, Fallara G, Tozzi M, et al. "Guideline of guidelines: Peyronie's disease." BJU Int. 2026;137(5):770–782. doi:10.1111/bju.70201

22. Manka MG, White LA, Yafi FA, et al. "Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation." J Sex Med. 2021;18(2):363–375. doi:10.1016/j.jsxm.2020.11.013

23. Ringel NE, Iglesia C. "Common benign chronic vulvar disorders." Am Fam Physician. 2020;102(9):550–557.

24. Potts BA, Belsante MJ, Peterson AC. "Intraurethral steroids are a safe and effective treatment for stricture disease in patients with biopsy-proven lichen sclerosus." J Urol. 2016;195(6):1790–1796. doi:10.1016/j.juro.2015.12.067

25. Hayden JP, Boysen WR, Peterson AC. "Medical management of penile and urethral lichen sclerosus with topical clobetasol improves long-term voiding symptoms and quality of life." J Urol. 2020;204(6):1290–1295. doi:10.1097/JU.0000000000001304

26. Wilkinson DJ, Lansdale N, Everitt LH, et al. "Foreskin preputioplasty and intralesional triamcinolone: a valid alternative to circumcision for balanitis xerotica obliterans." J Pediatr Surg. 2012;47(4):756–759. doi:10.1016/j.jpedsurg.2011.10.059

27. Katims AB, Edelblute BT, Tam AW, et al. "Long-term outcomes of laser incision and triamcinolone injection for the management of ureteroenteric anastomotic strictures." J Endourol. 2021;35(1):21–24. doi:10.1089/end.2020.0593

28. Meretyk S, Albala DM, Clayman RV, Denstedt JD, Kavoussi LR. "Endoureterotomy for treatment of ureteral strictures." J Urol. 1992;147(6):1502–1506. doi:10.1016/s0022-5347(17)37608-5

29. Ashraf J, Radford AR, Turner A, Subramaniam R. "Preliminary experience with instillation of triamcinolone acetonide into the urethra for idiopathic urethritis: a prospective pilot study." J Laparoendosc Adv Surg Tech A. 2017;27(11):1217–1221. doi:10.1089/lap.2017.0064

30. Augspurger RR, Wettlaufer JN. "Cushing's syndrome: complication of triamcinolone injection for urethral strictures in children." J Urol. 1980;123(6):932–933. doi:10.1016/s0022-5347(17)56200-x

31. EAU. Urethral Strictures: Disease Management in Males (2026), intralesional adjuncts and posterior endoluminal safety. Guideline.

32. EAU. Paediatric Urology: Phimosis and Other Abnormalities of the Penile Skin (2026). Guideline.

33. EAU. Sexual and Reproductive Health: Penile Curvature (2026). Guideline.

34. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." J Dtsch Dermatol Ges. 2026;24(4):566–584. doi:10.1111/ddg.70000. Full German S3 guideline, June 2025.